Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Super Group (SGHC) Limited Ordinary Shares (SGHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Super Group (SGHC) Limited Ordinary Shares trades at $11.1 (market cap $5.69B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.79% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Super Group (SGHC) Limited Ordinary Shares for 6 Days on average.
| KYMR | SGHC | |
|---|---|---|
Market Cap | $8.87B | $5.69B |
Volume | 779,107 | 2,162,759 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $15.59 |
52-Week Low | $55.80 | $8.52 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $5.23B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SGHC trades at $11.19, down 0.27% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 53.31% gross margins and 48.9% ROE, while revenue grew to $2.23B in 2025. Recent earnings missed expectations but analyst consensus remains unanimously bullish with 8 buy ratings. Technical indicators show selling pressure with moving averages signaling bearish momentum.
SGHC presents a compelling value opportunity with attractive valuation multiples (P/E 15.55, EV/EBITDA 8.43) and strong cash flow generation. However, recent earnings misses and bearish technical signals create near-term headwinds. The stock's outlook depends on Q3 earnings delivery and sustained sports betting momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →
